IS THERE A ROOM IN BULGARIA FOR RADIOTHERAPY OF GASTRIC CANCER?
Gastric cancer is the fourth most common cancer worldwide with one million new casesyearly and the second most frequent cause of cancer death. Although surgery is the leading treatment modality of gastric cancer the survival remains low (5- year survival is reported to be 25% in Europe and 60% in the Eastern world). The risk of locoregional recurrence grows with the increase of the tumor stage. In order to improve locoregional control a number of clinical studies in the last four decades have examined different strategies of adjuvant therapy, including chemotherapy, radiotherapy, chemoradiation with ambiguous results. Various regimens of radiotherapy alone, applied preand postoperatively or in combination with chemotherapy in pre- and postoperative settings have been studied. With the present article, the authors present the world experience of radiotherapy application in gastric carcinoma, supporting its introduction in to Bulgarian clinical practice. The study results concerning this topic have been discussed. SWOG/Intergroup 0116 study showed that postoperative chemoradiation leads to increased 5-year overall survival compared with surgery alone. A recent metaanalysis on randomized trials in operable gastric cancer, found that adjuvant radiotherapy leads to 20 % improvement in disease free survival and overall survival and found no subgroup of patients who do not benefit from adjuvant radiotherapy. The available data from the published studies and metaanalysis completely supports the introduction of chemoradiation for gastric cancer and in Bulgarian radiotherapy practice with the opportunity of gaining own experience.